Variability amongst urine toxicology amphetamine readings with concurrent administration of fenofibrate.

CONCLUSIONS: It is evident that different pathology laboratories may utilise different commercial urine drug-screen immunoassays in their toxicology analysis, with variability in the test specificities. Despite the relatively high prevalence of substance misuse in the population of psychiatric inpatients, there exists a need for increased vigilance towards the possibility of false-positive amphetamine results owing to likely cross-reactivity of fenofibrate with the test reagents. In cases where there is uncertainty when correlating clinically, or where false positives are suspected, gold-standard urine-sample analysis by mass spectrometry should be considered, particularly when the consequences for patients may include restrictive measures.
PMID: 28699773 [PubMed - as supplied by publisher]

Source: Australasian Psychiatry - July 1, 2017 Category: Psychiatry Authors: Dadlani N, Farrar A, Jones G Tags: Australas Psychiatry Source Type: research